Evaluating the role of anti-EBV antibodies as biomarkers for the evolution of multiple sclerosis: A longitudinal study.

Baseline anti-EBV antibody levels did not correlate with MRI, OCT or sNfL markers of disease activity, neurodegeneration, and clinical worsening over time, suggesting EBV's role in the evolution of MS is uncertain.